{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-063510","form_type":"8-K","ticker":"VTGN","cik":"0001411685","company_name":"Vistagen Therapeutics, Inc.","filed_at":"2026-09-25T13:11:02+00:00","discovered_at":"2026-09-25T13:12:00.546441+00:00","generated_at":"2026-10-12T13:19:47.946292+00:00","sec_items":["7.01","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.08,"calibrated_materiality_score":0.08,"confidence":"low","headline":"Vistagen files new September 2026 corporate presentation; no financial or clinical data in the text","bullets":["Exhibit 99.1 is a corporate presentation dated September 2026 titled 'Harnessing the therapeutic power and potential of brain regulation with nose-to-brain neurocircuitry.'","The appended exhibit contains only the title slide; no pipeline updates, trial results, cash balance, revenue or guidance figures were disclosed.","Filing signed September 25, 2026 by President and CEO Shawn K. Singh; registrant is Vistagen Therapeutics, Inc., South San Francisco, California.","No clinical, regulatory, financing or partnership event is described, so no directional read is possible from this filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-063510","json":"https://secwatch.observer/filing/0001628280-26-063510.json","markdown":"https://secwatch.observer/filing/0001628280-26-063510.md","text":"https://secwatch.observer/filing/0001628280-26-063510.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411685/000162828026063510/0001628280-26-063510-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411685/000162828026063510/vtgn-20260925.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T13:19:47.946292+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}